The Center for Drug Evaluation of the State Food and Drug Administration released the "Annual Report on the Progress of New Drug Registration Clinical Trials in China (2021)"

In order to fully grasp the progress of clinical trials for new drug registration in China, use information technology to improve drug supervision capabilities, disclose clinical trial progress information in a timely manner, and provide reference for new drug research and development, resource allocation, and drug review and approval, the Center for Drug Evaluation is based on the registration and approval of drug clinical tria.

This annual report is mainly based on the information of drug clinical trials registered in 2021, including drug types, varieties and target characteristics, indications, sponsor types, registration classification, trial classification, trial staging, special population trials, and clinical trial team leader uni.

Attachment: Annual Report on Progress of Clinical Trials for New Drug Registration in China (2021)

Drug Evaluation Center of the State Food and Drug Administration

June 7, 2022

Relevant attachments